InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,559.84
(
0.92%
)
US TECH 100
19,837.20
(
1.00%
)
Dow Jones
39,336.33
(
0.07%
)
Brent Oil
86.48
(
-0.98%
)
Bitcoin
56,485.51
(
-0.88%
)
Post# of 252491
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119981
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 11/03/2003 7:16:16 PM

Monday, November 03, 2003 7:16:16 PM

Post# of 252491
Allergan stung by quirk in Hatch-Waxman:

Drugs classified as antibiotics are not afforded exclusivity protection under the 1984 Hatch-Waxman act. AGN’s dry-eye drug, Restasis, is a reformulation of Cyclosporin, the old transplantation anti-rejection drug from NVS. But the FDA has now classified Restasis as an antibiotic, and Allergan is taking the unusual step of suing the FDA:

http://biz.yahoo.com/rc/031103/health_allergan_1.html

[IMHO: this newswire is needlessly confusing because it fails to mention the antibiotic quirk in Hatch-Waxman explicitly.]

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up